Asset Details
Do you wish to reserve the book?
Current status of synthetic hemozoin adjuvant: A preliminary safety evaluation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Current status of synthetic hemozoin adjuvant: A preliminary safety evaluation
Do you wish to request the book?
Current status of synthetic hemozoin adjuvant: A preliminary safety evaluation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Current status of synthetic hemozoin adjuvant: A preliminary safety evaluation
2016
Overview
•Hemozoin is a by-product of Plasmodium parasites.•Synthetic hemozoin (sHZ) is a potent adjuvant in vaccine formulations.•Optimized sHZ adjuvant is recently produced in a GLP-certified facility.•Optimized sHZ is safe, tolerable and has no toxicity in GLP non-clinical setting.
Although adjuvants are a “must-have” component of successful vaccines, there are very few adjuvants licensed for use in humans, there is therefore an urgent need to develop new and safer adjuvants. Synthetic hemozoin (sHZ), a chemical analog of hemozoin which is produced by the malaria parasite, exhibits a potent adjuvant effect which enhances antigen-specific immune responses to vaccines. The potency of sHZ adjuvanticity is not limited to malaria specific vaccines, it has also been demonstrated to be effective in influenza and dog allergy models. While the synthesis of uniformly sized sHZ with consistent characteristics has proven difficult, we have recently successfully optimized the manufacture of sHZ product with an optimal adjuvant effect. Here, we summarize recent developments on the adjuvant properties of optimized sHZ adjuvant, including its good laboratory practice (GLP) non-clinical safety profile in animals. These studies ensure the safety of optimized sHZ product to be readily used as vaccine adjuvant beforehand in veterinary medicine.
Publisher
Elsevier Ltd,Elsevier Limited
We currently cannot retrieve any items related to this title. Kindly check back at a later time.